The Experts below are selected from a list of 918 Experts worldwide ranked by ideXlab platform

Chihming Liao - One of the best experts on this subject based on the ideXlab platform.

  • efficacy of a novel pasteurella multocida vaccine against progressive Atrophic Rhinitis of swine
    2009
    Co-Authors: Shihling Hsuan, Chihming Liao, Chienjin Huang, Zengweng Chen, Weicheng Lee, James R Winton, Jiunnwang Liao, Terhsin Chen, Chwei Jang Chiou, Kuang Sheng Yeh
    Abstract:

    The efficacy of a novel vaccine composed of three short recombinant subunit Pasteurella multocida toxin (PMT) proteins in combination with a bi-valent P. multocida whole-cell bacterin (rsPMT-PM) was evaluated in field studies for prevention and control of progressive Atrophic Rhinitis (PAR) of swine at 15 conventional farrow-to-finish farms. Experimental piglets that were immunized twice with the rsPMT-PM vaccine developed detectable titers of neutralizing antibodies (greater than 1:8) that prevented the growth retardation and pathological lesions typically observed following challenge with authentic PMT. A total of 542 sows were vaccinated once or twice prior to parturition and serum neutralizing antibody titers were evaluated. Both single and double vaccination protocols induced neutralizing antibody titers of 1:16 or higher in 62% and 74% of sows, respectively. Notably, neither sows nor piglets at a farm experiencing a severe outbreak of PAR at the time of the vaccination trial had detectable antibody titers, but antibody titers increased significantly to 1:16 or higher in 40% of sows following double vaccination. During the year after vaccination, clinical signs of PAR decreased in fattening pigs and growth performance improved sufficiently to reduce the rearing period until marketing by 2 weeks. Collectively, these results indicate that the rsPMT-PM vaccine could be used to provide protective immunity for controlling the prevalence and severity of PAR among farm-raised swine.

  • immunogenicity and efficacy of three recombinant subunit pasteurella multocida toxin vaccines against progressive Atrophic Rhinitis in pigs
    2006
    Co-Authors: Chihming Liao, Chienjin Huang, Shihling Hsuan, Zengweng Chen, Weicheng Lee, Chengi Liu, James R Winton, Mawsheng Chien
    Abstract:

    Three short fragments of recombinant subunit Pasteurella multocida toxin (rsPMT) were constructed for evaluation as candidate vaccines against progressive Atrophic Rhinitis (PAR) of swine. PMT-specific antibody secreting cells and evidence of cellular immunity were detected in rsPMT-immunized pigs following authentic PMT challenge or homologous antigen booster. Piglets immunized with rsPMT fragments containing either the N-terminal or the C-terminal portions of PMT developed high titers of neutralizing antibodies. Pregnant sows immunized with rsPMT had higher levels of maternal antibodies in their colostrum than did those immunized with a conventional PAR-toxoid vaccine. Offspring from rsPMT vaccinated sows had better survival after challenge with a five-fold lethal dose of authentic PMT and had better growth performance after challenge with a sublethal dose of toxin. Our findings indicate these non-toxic rsPMT proteins are attractive candidates for development of a subunit vaccine against PAR in pigs.

Shihling Hsuan - One of the best experts on this subject based on the ideXlab platform.

  • efficacy of a novel pasteurella multocida vaccine against progressive Atrophic Rhinitis of swine
    2009
    Co-Authors: Shihling Hsuan, Chihming Liao, Chienjin Huang, Zengweng Chen, Weicheng Lee, James R Winton, Jiunnwang Liao, Terhsin Chen, Chwei Jang Chiou, Kuang Sheng Yeh
    Abstract:

    The efficacy of a novel vaccine composed of three short recombinant subunit Pasteurella multocida toxin (PMT) proteins in combination with a bi-valent P. multocida whole-cell bacterin (rsPMT-PM) was evaluated in field studies for prevention and control of progressive Atrophic Rhinitis (PAR) of swine at 15 conventional farrow-to-finish farms. Experimental piglets that were immunized twice with the rsPMT-PM vaccine developed detectable titers of neutralizing antibodies (greater than 1:8) that prevented the growth retardation and pathological lesions typically observed following challenge with authentic PMT. A total of 542 sows were vaccinated once or twice prior to parturition and serum neutralizing antibody titers were evaluated. Both single and double vaccination protocols induced neutralizing antibody titers of 1:16 or higher in 62% and 74% of sows, respectively. Notably, neither sows nor piglets at a farm experiencing a severe outbreak of PAR at the time of the vaccination trial had detectable antibody titers, but antibody titers increased significantly to 1:16 or higher in 40% of sows following double vaccination. During the year after vaccination, clinical signs of PAR decreased in fattening pigs and growth performance improved sufficiently to reduce the rearing period until marketing by 2 weeks. Collectively, these results indicate that the rsPMT-PM vaccine could be used to provide protective immunity for controlling the prevalence and severity of PAR among farm-raised swine.

  • immunogenicity and efficacy of three recombinant subunit pasteurella multocida toxin vaccines against progressive Atrophic Rhinitis in pigs
    2006
    Co-Authors: Chihming Liao, Chienjin Huang, Shihling Hsuan, Zengweng Chen, Weicheng Lee, Chengi Liu, James R Winton, Mawsheng Chien
    Abstract:

    Three short fragments of recombinant subunit Pasteurella multocida toxin (rsPMT) were constructed for evaluation as candidate vaccines against progressive Atrophic Rhinitis (PAR) of swine. PMT-specific antibody secreting cells and evidence of cellular immunity were detected in rsPMT-immunized pigs following authentic PMT challenge or homologous antigen booster. Piglets immunized with rsPMT fragments containing either the N-terminal or the C-terminal portions of PMT developed high titers of neutralizing antibodies. Pregnant sows immunized with rsPMT had higher levels of maternal antibodies in their colostrum than did those immunized with a conventional PAR-toxoid vaccine. Offspring from rsPMT vaccinated sows had better survival after challenge with a five-fold lethal dose of authentic PMT and had better growth performance after challenge with a sublethal dose of toxin. Our findings indicate these non-toxic rsPMT proteins are attractive candidates for development of a subunit vaccine against PAR in pigs.

Mawsheng Chien - One of the best experts on this subject based on the ideXlab platform.

  • immunogenicity and efficacy of three recombinant subunit pasteurella multocida toxin vaccines against progressive Atrophic Rhinitis in pigs
    2006
    Co-Authors: Chihming Liao, Chienjin Huang, Shihling Hsuan, Zengweng Chen, Weicheng Lee, Chengi Liu, James R Winton, Mawsheng Chien
    Abstract:

    Three short fragments of recombinant subunit Pasteurella multocida toxin (rsPMT) were constructed for evaluation as candidate vaccines against progressive Atrophic Rhinitis (PAR) of swine. PMT-specific antibody secreting cells and evidence of cellular immunity were detected in rsPMT-immunized pigs following authentic PMT challenge or homologous antigen booster. Piglets immunized with rsPMT fragments containing either the N-terminal or the C-terminal portions of PMT developed high titers of neutralizing antibodies. Pregnant sows immunized with rsPMT had higher levels of maternal antibodies in their colostrum than did those immunized with a conventional PAR-toxoid vaccine. Offspring from rsPMT vaccinated sows had better survival after challenge with a five-fold lethal dose of authentic PMT and had better growth performance after challenge with a sublethal dose of toxin. Our findings indicate these non-toxic rsPMT proteins are attractive candidates for development of a subunit vaccine against PAR in pigs.

James R Winton - One of the best experts on this subject based on the ideXlab platform.

  • efficacy of a novel pasteurella multocida vaccine against progressive Atrophic Rhinitis of swine
    2009
    Co-Authors: Shihling Hsuan, Chihming Liao, Chienjin Huang, Zengweng Chen, Weicheng Lee, James R Winton, Jiunnwang Liao, Terhsin Chen, Chwei Jang Chiou, Kuang Sheng Yeh
    Abstract:

    The efficacy of a novel vaccine composed of three short recombinant subunit Pasteurella multocida toxin (PMT) proteins in combination with a bi-valent P. multocida whole-cell bacterin (rsPMT-PM) was evaluated in field studies for prevention and control of progressive Atrophic Rhinitis (PAR) of swine at 15 conventional farrow-to-finish farms. Experimental piglets that were immunized twice with the rsPMT-PM vaccine developed detectable titers of neutralizing antibodies (greater than 1:8) that prevented the growth retardation and pathological lesions typically observed following challenge with authentic PMT. A total of 542 sows were vaccinated once or twice prior to parturition and serum neutralizing antibody titers were evaluated. Both single and double vaccination protocols induced neutralizing antibody titers of 1:16 or higher in 62% and 74% of sows, respectively. Notably, neither sows nor piglets at a farm experiencing a severe outbreak of PAR at the time of the vaccination trial had detectable antibody titers, but antibody titers increased significantly to 1:16 or higher in 40% of sows following double vaccination. During the year after vaccination, clinical signs of PAR decreased in fattening pigs and growth performance improved sufficiently to reduce the rearing period until marketing by 2 weeks. Collectively, these results indicate that the rsPMT-PM vaccine could be used to provide protective immunity for controlling the prevalence and severity of PAR among farm-raised swine.

  • immunogenicity and efficacy of three recombinant subunit pasteurella multocida toxin vaccines against progressive Atrophic Rhinitis in pigs
    2006
    Co-Authors: Chihming Liao, Chienjin Huang, Shihling Hsuan, Zengweng Chen, Weicheng Lee, Chengi Liu, James R Winton, Mawsheng Chien
    Abstract:

    Three short fragments of recombinant subunit Pasteurella multocida toxin (rsPMT) were constructed for evaluation as candidate vaccines against progressive Atrophic Rhinitis (PAR) of swine. PMT-specific antibody secreting cells and evidence of cellular immunity were detected in rsPMT-immunized pigs following authentic PMT challenge or homologous antigen booster. Piglets immunized with rsPMT fragments containing either the N-terminal or the C-terminal portions of PMT developed high titers of neutralizing antibodies. Pregnant sows immunized with rsPMT had higher levels of maternal antibodies in their colostrum than did those immunized with a conventional PAR-toxoid vaccine. Offspring from rsPMT vaccinated sows had better survival after challenge with a five-fold lethal dose of authentic PMT and had better growth performance after challenge with a sublethal dose of toxin. Our findings indicate these non-toxic rsPMT proteins are attractive candidates for development of a subunit vaccine against PAR in pigs.

Weicheng Lee - One of the best experts on this subject based on the ideXlab platform.

  • efficacy of a novel pasteurella multocida vaccine against progressive Atrophic Rhinitis of swine
    2009
    Co-Authors: Shihling Hsuan, Chihming Liao, Chienjin Huang, Zengweng Chen, Weicheng Lee, James R Winton, Jiunnwang Liao, Terhsin Chen, Chwei Jang Chiou, Kuang Sheng Yeh
    Abstract:

    The efficacy of a novel vaccine composed of three short recombinant subunit Pasteurella multocida toxin (PMT) proteins in combination with a bi-valent P. multocida whole-cell bacterin (rsPMT-PM) was evaluated in field studies for prevention and control of progressive Atrophic Rhinitis (PAR) of swine at 15 conventional farrow-to-finish farms. Experimental piglets that were immunized twice with the rsPMT-PM vaccine developed detectable titers of neutralizing antibodies (greater than 1:8) that prevented the growth retardation and pathological lesions typically observed following challenge with authentic PMT. A total of 542 sows were vaccinated once or twice prior to parturition and serum neutralizing antibody titers were evaluated. Both single and double vaccination protocols induced neutralizing antibody titers of 1:16 or higher in 62% and 74% of sows, respectively. Notably, neither sows nor piglets at a farm experiencing a severe outbreak of PAR at the time of the vaccination trial had detectable antibody titers, but antibody titers increased significantly to 1:16 or higher in 40% of sows following double vaccination. During the year after vaccination, clinical signs of PAR decreased in fattening pigs and growth performance improved sufficiently to reduce the rearing period until marketing by 2 weeks. Collectively, these results indicate that the rsPMT-PM vaccine could be used to provide protective immunity for controlling the prevalence and severity of PAR among farm-raised swine.

  • immunogenicity and efficacy of three recombinant subunit pasteurella multocida toxin vaccines against progressive Atrophic Rhinitis in pigs
    2006
    Co-Authors: Chihming Liao, Chienjin Huang, Shihling Hsuan, Zengweng Chen, Weicheng Lee, Chengi Liu, James R Winton, Mawsheng Chien
    Abstract:

    Three short fragments of recombinant subunit Pasteurella multocida toxin (rsPMT) were constructed for evaluation as candidate vaccines against progressive Atrophic Rhinitis (PAR) of swine. PMT-specific antibody secreting cells and evidence of cellular immunity were detected in rsPMT-immunized pigs following authentic PMT challenge or homologous antigen booster. Piglets immunized with rsPMT fragments containing either the N-terminal or the C-terminal portions of PMT developed high titers of neutralizing antibodies. Pregnant sows immunized with rsPMT had higher levels of maternal antibodies in their colostrum than did those immunized with a conventional PAR-toxoid vaccine. Offspring from rsPMT vaccinated sows had better survival after challenge with a five-fold lethal dose of authentic PMT and had better growth performance after challenge with a sublethal dose of toxin. Our findings indicate these non-toxic rsPMT proteins are attractive candidates for development of a subunit vaccine against PAR in pigs.